Circulating Cell Free DNA (ccfDNA): Is It The Future of Breast Cancer Diagnosis?

Document Type : Mini-reviews

Authors

1 Department of Biochemistry, Faculty of Pharmacy, Sinai University - Arish Branch, Arish, Egypt.

2 Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

3 Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.

Abstract

Recently, liquid biopsies have emerged as a very promising diagnostic technique with a number of benefits over traditional invasive techniques. Novel approaches to Circulating cell-free nucleic acid (cfDNA) detection in blood have provided new, rapid, convenient, minimally invasive, and sensitive biomarkers for cancer diagnosis, prognosis, and monitoring of response to therapy. Circulating cfDNA, also known as circulating tumor nucleic acid (ctDNA), are one of several significant biomarkers that may be obtained from liquid biopsies. They are widely studied as promising biomarker candidates in the diagnosis and prognosis of cancer. Circulating cfDNA analysis may reveal details on the mutation profile of tumor cells. Many of these markers may be useful to clinicians in choosing therapies and in patient follow-up. Therefore, a new avenue in personalized medicine is represented by DNA-based diagnostics. cfDNA application in breast cancer is expected to be employed in ordinary clinical practice. Classification and treatment choices for breast cancer are now determined by tumor analysis; however, cfDNA may be examined from a straightforward, non-invasive blood sample and contain many characteristics of the original tumor. cfDNA may play a role as novel biomarkers in both early-stage and metastatic breast cancer for screening, diagnosis, recurrence detection after surgery, follow-up, detection of mutations, prognosis, and treatment monitoring.

Keywords

Main Subjects

Records of Pharmaceutical and Biomedical Sciences
Volume 9, Issue 1
Chemistry
March 2025
Pages 136-146

Files

Share

How to cite

Statistics